Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development.
about
Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice.Current prospects and challenges for epilepsy gene therapyAdenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy.The galanin-R2 agonist AR-M1896 reduces glutamate toxicity in primary neural hippocampal cells.Gene therapy in epilepsy.GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models.Recent advancements in stem cell and gene therapies for neurological disorders and intractable epilepsy.Neuromodulation in epilepsy.In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: implication for limbic seizures.Neuropeptides as targets for the development of anticonvulsant drugs.Encapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus.The clinical potential of antiepileptic gene therapy.Adeno-associated virus vectors: potential applications for cancer gene therapy.Galanin receptors and ligands.Neuroprotective strategies to avert seizure-induced neurodegeneration in epilepsy.The promise of gene therapy for the treatment of epilepsy.Somatostatin: an endogenous antiepilepticCell and gene therapies for refractory epilepsy.Neuropeptide Y overexpression using recombinant adeno-associated viral vectors.Adeno-associated virus vector-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity.Commentary: a skeptical view of experimental gene therapy to block epileptogenesis.Inhibitory role of the spinal galanin system in the control of micturition.Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma.Anticonvulsant neuropeptides as drug leads for neurological diseases.Novel approaches to epilepsy treatment.Progress in gene therapy for neurological disorders.Potential mechanisms and clinical applications of mild hypothermia and electroconvulsive therapy on refractory status epilepticus.Neurotrophin-3 mRNA a putative target of miR21 following status epilepticus.Glutamatergic Mechanisms Associated with Seizures and Epilepsy.Altered gene expression profile in a mouse model of SCN8A encephalopathy.A promising genetic approach for the treatment of epilepsyOn demand up-regulation of therapeutic genes in the brain: fiction or reality?Structural consequences of Kcna1 gene deletion and transfer in the mouse hippocampus.Altered Norbin Expression in Patients with Epilepsy and a Rat Model.Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo.Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus.Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy.Assessment of hippocampal adeno-associated viral vector gene delivery via frameless stereotaxis in a nonhuman primate.
P2860
Q24537325-0A3E10FE-88E5-473B-B9D1-42D9FE3666B4Q27002627-29A09599-7CD7-47DC-8756-CD1733FEBB73Q30605561-8CDF0089-2CA4-4991-92E0-30C4323D6D30Q33225947-025AE1AF-2FBB-48DB-BFA2-0057F03EBB6DQ33960096-3A7802D6-105F-4A08-8003-2399E1E9F93EQ34093567-AD1FB287-DC20-4BD7-A950-20A21E3ADE77Q34098055-4D8DF271-DEF9-445E-B0E6-5AB0663E04FCQ34196412-B6763870-8DF0-4125-8FD8-92869C5387A3Q34293701-5A5AB257-C4AA-4E19-A746-CC1BFA52D471Q34413859-6B1AFC03-52E6-4C42-8D53-F01039013F93Q35045578-95B01FE5-B38A-49C8-A914-EAA29E8E5C1BQ35925614-9C87E2D5-0114-4CC9-9AC3-55458493645FQ36165834-8B05F333-706C-452D-8145-7859AE2E29B6Q36451712-9AB8D8A0-58E3-428E-BB6E-1704BECC8C30Q36850257-864B9736-FA7B-47EC-8CBC-1635B4D30D12Q37021317-F44DDBA3-D037-479D-9671-C9663EF82A9FQ37067748-C53CDDC4-FF96-4FAE-82F8-1ACB8ADFD892Q37211817-71BE7BD9-6D81-49A5-BE00-3E78FE722D58Q37426975-4FE223CC-446B-46B0-9CD1-68A70B92B440Q37426979-58085367-EA0F-4228-90BA-FF98E21F6338Q37426987-35239ACC-092F-45D9-8978-04542C458A3AQ37577022-1910FB99-0482-4C0A-8650-FA870381E6CCQ37690752-0587C6AA-DA99-4731-8236-A504B23CE725Q37845684-147AA983-1288-40C5-862C-6943B5E5D2ADQ38056185-5ECD34C8-ACC1-4DB9-8772-8F7DFF70A854Q38100997-FB834EBE-8360-4EFB-8F1B-AF5CFD4D85E5Q38286238-64272F61-A7F3-42BC-9CE9-FD4F03E7ACA1Q38330929-E2D0271E-C151-45AC-85E1-F47B6B537BC7Q38535033-967A1978-4E05-431C-A4D7-12974A4CBF51Q39194220-064CFD80-0A03-4942-BD42-17530B22F27EQ41831834-819E3C45-D879-4FDA-B2BC-B63D1C3FF122Q42008294-BA28D032-9A00-4731-AA21-5E5189CE1742Q42567985-6FEC4064-1CF4-4345-9BA4-3B556487F607Q42630091-1BBFFBD5-92F0-48E3-B7A9-4A11D75AD08CQ43051288-43FD5D61-EFD7-4431-9C2B-248026EFACCDQ43134453-A007BD48-5D56-4F94-8FEE-DFFBD74B727FQ45877519-E0B79B98-5F23-48E1-A082-629AA4286406Q48944878-B1DC5E35-A758-4FCB-807D-C2B930B714B7
P2860
Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Recombinant AAV-mediated expre ...... uppresses seizure development.
@en
type
label
Recombinant AAV-mediated expre ...... uppresses seizure development.
@en
prefLabel
Recombinant AAV-mediated expre ...... uppresses seizure development.
@en
P2093
P2860
P1476
Recombinant AAV-mediated expre ...... uppresses seizure development.
@en
P2093
Cristina Richichi
Deborah Young
En-Ju D Lin
Kristin Baer
Matthew J During
P2860
P304
P356
10.1046/J.1460-9568.2003.02926.X
P407
P577
2003-10-01T00:00:00Z